4-羧基苯基异硫氰酸酯 | 2131-62-6

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羧基苯基异硫氰酸酯
• 英文名称: 4-isothiocyanatobenzoic acid
• 英文别名: 4-carboxyphenyl isothiocyanate；4-Isothiocyanato-benzoesaeure；4-Carboxy-phenylisothiocyanat
• CAS: 2131-62-6
• 化学式: C₈H₅NO₂S
• mdl: MFCD00041369
• 分子量: 179.199
• InChiKey: RBEFRYQKJYMLCC-UHFFFAOYSA-N

物化性质

• 熔点：
  220 °C
• 沸点：
  361.6±25.0 °C(Predicted)
• 密度：
  1.27
• 闪点：
  173℃
• 稳定性/保质期：
  避免氧化物接触，危险分解产物包括一氧化碳、二氧化碳和硫氧化物（包括硫氧化物和二氧化硫）。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  KEEP COLD, LACHRYMATOR, TOXIC
• 危险品标志：
  Xn,T
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2930909090
• 危险品运输编号：
  2811
• 储存条件：
  冷藏应储存在阴凉、干燥处，并存放于密闭容器中。

SDS

Name:	4-Isothiocyanatobenzoic acid 98% Material Safety Data Sheet
Synonym:	4-Carboxyphenyl isothiocyanat
CAS:	2131-62-6

Section 1 - Chemical Product MSDS Name:4-Isothiocyanatobenzoic acid 98% Material Safety Data Sheet
Synonym:4-Carboxyphenyl isothiocyanat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2131-62-6	4-Isothiocyanatobenzoic acid	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2131-62-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 220 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5NO2S
Molecular Weight: 179.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Moisture sensitive.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, sulfur oxides (SOx), including sulfur oxide and sulfur dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2131-62-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Isothiocyanatobenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 2131-62-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2131-62-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2131-62-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羧基苯基异硫氰酸酯 在 肼 作用下， 以 四氢呋喃 为溶剂， 生成 4-(4-羧苯苯基)-3-氨基硫脲
  参考文献：
  名称：

  鉴定小非肽基分子的血小板生成活性的药效基团。1.发现和优化水杨醛硫代半胱氨酸血小板生成素模拟物。

  摘要：

  高通量筛选导致发现了硫半脲类血小板生成素模拟物。该系列与先前确定的吡唑-4-亚甲基肼类之间共有一个药效基团假设，可快速优化硫代半氨基甲酮的药效和功效。高通量化学和纯化技术的应用可以快速阐明结构活性关系。

  DOI：

  10.1021/jm025535c
• 作为产物：
  描述：

  对氨基苯甲酸 在 三乙胺 、 N,N'-硫羰基二咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以90%的产率得到4-羧基苯基异硫氰酸酯
  参考文献：
  名称：

  4-噻唑烷酮衍生物作为人二氢乳清酸酯脱氢酶的新型抑制剂的合成，构效关系和结合模式分析

  摘要：

  合成了一系列的4-噻唑烷酮衍生物，并作为新型人二氢乳清酸脱氢酶（h DHODH）抑制剂进行了评估。化合物26和31的IC 50值分别为1.75和1.12μM。构效关系进行了总结。进一步的结合模式分析表明，化合物31可以与Tyr38形成氢键，并与Ala55形成水介导的氢键，这对于维持该系列化合物的生物活性可能是必需的。R上苯基对位或间位的进一步结构优化将导致鉴定更有效的hDHODH抑制剂。

  DOI：

  10.1039/c7md00081b

文献信息

• Mechanism-Based Isocoumarin Inhibitors for Human Leukocyte Elastase. Effect of the 7-Amino Substituent and 3-Alkoxy Group in 3-Alkoxy-7-amino-4-chloroisocoumarins on Inhibitory Potency
  作者：John E. Kerrigan、Jozef Oleksyszyn、Chih-Min Kam、Joe Selzler、James C. Powers

  DOI：10.1021/jm00003a017

  日期：1995.2

  prepared and evaluated as inhibitors of human leukocyte elastase (HLE). In addition, a new series of acyl, urea, and carbamate derivatives of 7-amino-4-chloro-3-methoxyisocoumarin (1), 7-amino-4-chloro-3-propoxyisocoumarin (3), and 7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin (6) have been synthesized. Most of the synthesized compounds are very potent inhibitors of HLE with kobs/[I] values between 10(4)

  已经制备了具有各种3-烷氧基取代基的一系列3-烷氧基-7-氨基-4-氯异香豆素，并将其评估为人白细胞弹性蛋白酶（HLE）的抑制剂。此外，还推出了一系列新的7-氨基-4-氯-3-甲氧基异香豆素（1），7-氨基-4-氯-3-丙氧基异香豆素（3）和7-氨基-香豆素的酰基，脲和氨基甲酸酯衍生物已经合成了4-氯-3-（2-溴乙氧基）异香豆素（6）。大多数合成的化合物都是非常有效的HLE抑制剂，其kobs / [I]值在10（4）和10（6）M-1 s-1之间。异香豆素环7-氨基位置的疏水取代基为HLE提供了最佳的选择性和抑制能力。在2-溴乙氧基系列中，具有PhNHCONH 7取代基的化合物24的kobs / [I]值为1.2 x 10（6）M-1 s-1，对HLE具有很高的选择性，并且是最有效的HLE抑制剂。经过HLE测试。在长链L-苯丙氨酰基衍生物中，kobs / [I]值为1.8 x 10（5）M-1
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• NAMPT/HDAC双靶点抑制剂及其制备方法
  申请人：聚缘（上海）生物科技有限公司

  公开号：CN106916101B

  公开（公告）日：2020-05-01

  本发明公开了一种NAMPT/HDAC双靶点抑制剂及其制备方法；该双靶点抑制剂为酰胺类衍生物及其药学上可接受的盐，其结构通式如式(I)所示：(I)。药理实验表明，本发明所述的衍生物或盐，对烟酰胺磷酸核糖转移酶和组蛋白去乙酰化酶均具有很强的抑制活性，而且具有较强的体外抗肿瘤活性和优秀的体内抑瘤效果。本发明还提供了上述衍生物及其药学上可接受的盐的制备方法，以及在制备烟酰胺磷酸核糖转移酶抑制剂、组蛋白去乙酰化酶抑制剂和抗肿瘤药物中的应用。
• Synthesis and Biological Evaluation of Arylthiourea Derivatives with Antitubercular Activity
  作者：Rusong Luo、Tuomo Laitinen、Liyan Teng、Tapio Nevalainen、Maija Lahtela-Kakkonen、Baofu Zheng、Honghai Wang、Antti Poso、Xuelian Zhang

  DOI：10.2174/1570180811310070012

  日期：2013.6.1

  Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.

  结核病（TB）是一种由结核分枝杆菌（M. tuberculosis）引起的传染性疾病，仍然是全球公共卫生的最致命威胁之一。耐药TB菌株的出现以及与HIV的共同感染进一步复杂化了结核病的治疗。本文描述了一系列化合物的合成与表征，随后对其抗菌活性进行了评估，特别是针对结核分枝杆菌。几种新型芳基硫脲衍生物显示出卓越的活性（最低MIC=0.09 μg/ml），能有效对抗包括耐药菌株在内的结核分枝杆菌。这些结果表明，这些化合物是有希望的新型抗结核药物开发候选者。
• [EN] PI-3 KINASE INHIBITOR PRODRUGS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE PI-3 KINASE
  申请人：SEMAFORE PHARMACEUTICALS INC

  公开号：WO2004089925A1

  公开（公告）日：2004-10-21

  The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

  这项发明提供了PI-3激酶抑制剂的新型前药。这些新型化合物是LY294002及其类似物，包括可逆性季铵化胺。

表征谱图